Wedge Capital Management L L P Eagle Pharmaceuticals, Inc. Transaction History

Wedge Capital Management L L P

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Jul 10, 2020	SELL	$43.24 - $55.02 $266,315 - $338,868	-6,159 Closed	0 $0
Q1 2020 Apr 13, 2020	BUY	$34.37 - $60.07 $25,811 - $45,112	751 Added 13.89%	6,159 $283,000
Q4 2019 Jan 15, 2020	BUY	$54.32 - $64.31 $36,666 - $43,409	675 Added 14.26%	5,408 $325,000
Q3 2019 Nov 01, 2019	BUY	$53.25 - $59.98 $252,032 - $283,885	4,733 New	4,733 $268,000
Q3 2018 Nov 01, 2018	SELL	$66.65 - $83.86 $448,687 - $564,545	-6,732 Closed	0 $0
Q2 2018 Jul 31, 2018	BUY	$51.25 - $76.62 $345,015 - $515,805	6,732 New	6,732 $509,000

8.6M

100

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

Get notified when there are updates to the investment portfolio of Wedge Capital Management L L P, based on Form 13F filings with the SEC.

Stay updated on Wedge Capital Management L L P with notifications on news.